HONG KONG – Asian drugmakers are increasingly embracing the artificial intelligence (AI) technology for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-backed biotech firm Twoxar Inc.
HONG KONG – Chinese drugmaker Luye Pharma Group Ltd. said it filed an NDA submission to the U.S. FDA for Rykindo, its novel risperidone extended-release microsphere for injection, to treat schizophrenia and bipolar disorder. It could become the first innovative drug developed by China to get marketing clearance in the U.S.
HONG KONG – Asian drugmakers are increasingly embracing the artificial intelligence (AI) technology for drug discovery. The latest example is Japanese drug developer Ono Pharmaceutical Co. Ltd., which recently entered a partnership with U.S. AI-backed biotech firm Twoxar Inc.
HONG KONG – Chinese drugmaker Luye Pharma Group Ltd. said it filed an NDA submission to the U.S. FDA for Rykindo, its novel risperidone extended-release microsphere for injection, to treat schizophrenia and bipolar disorder. It could become the first innovative drug developed by China to get marketing clearance in the U.S.
HONG KONG – Chinese vaccine developer Cansino Biologics Inc. is on its way to becoming the seventh pre-revenue biotech to list in Hong Kong. Expected to debut on the main board of the Hong Kong Stock Exchange (HKEX) on March 28, Cansino aims to raise up to HK$1.26 billion (US$160.5 million).
HONG KONG – Seoul, South Korea-based SN Bioscience Inc. has developed a drug delivery technology to make injecting antitumor drugs into human bodies possible. Two months after it secured KRW5 billion (US$4.4 million) from South Korea's energy and chemical giant, OCI Co., in a series A financing, the firm is expecting another investment of $3.5 million in the coming weeks.
HONG KONG – Chinese vaccine developer Cansino Biologics Inc. is on its way to becoming the seventh pre-revenue biotech to list in Hong Kong. Expected to debut on the main board of the Hong Kong Stock Exchange (HKEX) on March 28, Cansino aims to raise up to HK$1.26 billion (US$160.5 million).
HONG KONG – Seoul, South Korea-based SN Bioscience Inc. has developed a drug delivery technology to make injecting antitumor drugs into human bodies possible. Two months after it secured KRW5 billion (US$4.4 million) from South Korea's energy and chemical giant, OCI Co., in a series A financing, the firm is expecting another investment of $3.5 million in the coming weeks. The funding will help it spearhead the development of its core asset, SNB-101, to treat pancreatic cancer.
